NUGEN MEDICAL DEVICES Stock Price, News & Analysis

NuGen Medical Devices Inc. (NGMDF) is a healthcare company in the medical devices industry that focuses on needle-free subcutaneous drug delivery. According to company disclosures in multiple press releases, NuGen describes itself as a developer of needle-free devices to administer therapeutics subcutaneously and as a company that is marketing and selling its next-generation InsuJet™ needle-free injection system, which is designed to improve the lives of people living with diabetes.

Core business and focus

NuGen states that it develops next-generation needle-free devices for subcutaneous drug delivery. Its flagship product is the InsuJet™ needle-free injection system, which the company describes as a device for the administration of insulin and other therapeutics without the use of traditional needles. NuGen reports that InsuJet™ is approved for sale in 42 countries and is being commercialized through distribution partners and e‑commerce platforms in various markets, including Canada, France and other regions referenced in its news releases.

The company consistently characterizes itself as a leading developer of needle-free devices to administer therapeutics subcutaneously. Its communications emphasize needle-free insulin delivery for people with diabetes and the broader potential of needle-free technology for subcutaneous medicines and biosimilar protein products.

InsuJet™ needle-free injection system

NuGen’s public communications describe InsuJet™ as a needle-free insulin-delivery device that uses a high-pressure micro‑jet to deliver standard U‑100 insulin through the skin without a needle. The company states that InsuJet™ is designed for adults and children aged six and over and that it delivers U‑100 insulin via a precise high‑pressure jet through a nozzle that penetrates the skin without needles. NuGen notes that InsuJet™ is CE marked and described as compliant with European medical-device standards in its French market materials.

In its French e‑commerce launch announcement, NuGen highlights several InsuJet™ attributes, including reusability for up to 5,000 injections, compatibility with U‑100 insulin in 3 mL cartridges, prefilled insulin pens, or 10 mL vials, and the absence of sharps-disposal requirements due to needle-free operation. The company also cites clinical studies that, according to its press release, demonstrate faster insulin absorption, tighter glycaemic control, and higher patient satisfaction versus traditional needles, in the context of diabetes care.

Geographic commercialization and distribution partnerships

NuGen’s news releases describe a commercialization strategy that relies on distribution partners and branded channels in different markets:

• Canada: The company reports a Canada‑wide launch of InsuJet™ and later expansion of distribution across Canada. It notes that InsuJet™ is available through pharmacy retailers and distributors such as London Drugs, Pattison Food Group, Pure Integrative Pharmacies, Imperial Distributors, Shoppers Drug Mart, McKesson Canada, and Kohl & Frisch, as well as a national retail partner referenced in its April 2025 update.
• France: NuGen announced the launch of InsuJet.fr, a dedicated French‑language information and e‑commerce site for InsuJet™, developed with its exclusive distributor Sol‑Millennium France. The company states that this platform provides access to product details, educational resources and secure online purchasing for people living with diabetes in France.
• United Kingdom and additional territories: NuGen entered into a license, supply and distribution agreement with EziAutoJector® Limited, granting EziAutoJector a license to distribute, market and promote NuGen’s needle-free device under the EziAutoJector® brand for U‑100 insulin and other subcutaneous biosimilar protein products in multiple countries. NuGen later reported that EziAutoJector® products received NHS Drug Tariff approval in the UK, enabling NHS-funded access for eligible patients prescribed the device.

Across these announcements, NuGen emphasizes collaboration with distributors, wholesalers, and clinical partners to expand access to its needle-free technology in diabetes care and related therapeutic areas.

New needle-free injection system with internal cartridge technology

In a separate press release, NuGen describes research and development of a next-generation needle-free injection system based on an internal cartridge design. The company states that this innovation is protected under international patent WO2021206553, granted in the European Union and China and pending in Canada and the United States. According to NuGen, the design integrates a sterile internal insulin cartridge into its proprietary needle-free autoinjector.

NuGen contrasts this new design with existing systems such as InsuJet™, which it says require external connectors to manually draw insulin into a temporary reservoir. By embedding a prefilled cartridge directly into the needle-free platform, the company states that the new system removes the need for external adaptors and manual filling, and it highlights a backflow control mechanism intended to address high-pressure backflow challenges specific to jet injection. NuGen’s description emphasizes simplified operation for patients and caregivers, with the goal of reducing training time and improving compliance.

Therapeutic focus and clinical context

NuGen’s public materials focus heavily on diabetes management. The company repeatedly states that InsuJet™ is designed to improve the lives of diabetics and people living with diabetes worldwide. In its French market announcement, NuGen cites data from France’s National Health Insurance to illustrate the scale of diabetes as a public-health challenge and frames needle anxiety and delayed insulin initiation as issues that needle-free insulin delivery seeks to address.

NuGen also references clinical interest in InsuJet™. The device was pre‑launched at the Congress of the Société Francophone du Diabète, where the company reports it was named “Innovation of the Year in Insulin Therapy.” NuGen notes that numerous hospitals requested demonstrations and that clinical evaluations were initiated at the Institut de Diabétologie et Nutrition du Centre (IDNC) to support national reimbursement and further validate clinical and economic aspects of needle-free insulin delivery.

Environmental and healthcare system considerations

In its UK‑focused communication about the EziAutoJector® product line, NuGen highlights environmental and system-level impacts associated with needle-free insulin delivery. The company states that by transitioning to EziAutoJector®, each patient eliminates the use of over 1,000 single-use insulin needles annually, which it links to a reduction in biohazardous waste and in the environmental footprint associated with collection and disposal of sharps. NuGen connects this to sustainability and cost-efficiency goals within the UK’s National Health Service (NHS).

Capital, governance and strategic investors

NuGen has reported several corporate developments related to capital structure and governance. In a press release on a private placement of secured convertible debentures, the company announced that Sol‑Millennium Medical HK Limited and Nature Health Development (Hong Kong) Co. Limited completed a strategic investment through the acquisition of secured convertible debentures. NuGen indicated that proceeds are intended for working capital, expansion of production, and fulfillment of increasing global sales purchase orders.

Following this financing, NuGen disclosed that its shareholders approved Sol‑M and Nature Health as new Control Persons under TSX Venture Exchange policies, based on potential ownership levels if the debentures and related securities are converted and exercised. The company also announced board and leadership changes, including the appointment of nominees of Sol‑M and Nature Health as directors and the appointment of an Executive Chairman and, subsequently, a new Chief Executive Officer.

Financial performance commentary

In its release of annual financial results, NuGen described a period of commercial ramp up for InsuJet™. The company reported that orders announced earlier in the year were shipped in the fourth quarter and that sales were recognized at that time. NuGen characterized the year as a record year of revenue and noted increases in gross profit, along with reductions in selling, general and administrative expenses and a lower loss from operations. It also referenced improvements to its balance sheet through renegotiation of long-term debt terms and completion of the secured convertible debenture financing.

These financial disclosures are presented by the company in the context of expanding manufacturing, building inventory, and developing new products, all tied to its needle-free drug delivery focus.

Position within the medical devices and healthcare sector

Within the broader healthcare sector, NuGen identifies itself as operating in the medical devices industry, with a specific emphasis on needle-free subcutaneous drug delivery. Its communications consistently focus on devices for the administration of insulin and other therapeutics under the skin without needles. The company’s activities, as described in its news releases, include device development, regulatory approvals in multiple jurisdictions, partnerships with medical device distributors and pharmaceutical-focused entities, and engagement with clinical and professional communities in diabetes care.

Stock information and trading

NuGen Medical Devices Inc. is referenced in its press releases as trading on the TSX Venture Exchange under the symbol NGMD. On Stock Titan, the company is associated with the OTC symbol NGMDF. The available information does not reference any delisting, deregistration, merger completion, or bankruptcy filing, and there are no SEC filings listed in the provided data.

FAQs about NuGen Medical Devices Inc. (NGMDF)

• What does NuGen Medical Devices Inc. do?
  NuGen Medical Devices Inc. develops needle-free devices for subcutaneous drug delivery. The company markets and sells its InsuJet™ needle-free injection system, which it describes as designed to improve the lives of people living with diabetes by enabling insulin administration without traditional needles.
• What is InsuJet™?
  InsuJet™ is NuGen’s flagship needle-free injection system for delivering standard U‑100 insulin and other therapeutics subcutaneously. According to the company, it uses a high‑pressure micro‑jet to penetrate the skin without a needle, is reusable for a large number of injections, and is compatible with commonly used U‑100 insulin formats.
• In how many countries is InsuJet™ approved?
  NuGen states in its press releases that InsuJet™ is approved for sale in 42 countries. This figure is repeated across multiple company communications describing its global commercialization footprint.
• Which markets has NuGen highlighted for InsuJet™ distribution?
  NuGen’s news releases highlight activity in Canada, where InsuJet™ has been launched nationally through pharmacy retailers and distributors, and in France, where the company has introduced a dedicated French-language e‑commerce platform. The company also references a partnership with EziAutoJector® Limited for distribution in the United Kingdom and other territories.
• What is the EziAutoJector® relationship with NuGen?
  NuGen entered into a license, supply and distribution agreement with EziAutoJector® Limited, granting EziAutoJector a license to distribute, market and promote NuGen’s needle-free device under the EziAutoJector® brand for U‑100 insulin and other subcutaneous biosimilar protein products in multiple countries. NuGen later reported NHS Drug Tariff approval for the EziAutoJector® product line in the UK.
• Does NuGen focus only on diabetes?
  NuGen’s communications focus strongly on diabetes and insulin delivery, describing InsuJet™ as designed to improve the lives of diabetics and people living with diabetes. In its partnership with EziAutoJector®, the company also references potential use with subcutaneous biosimilar protein products, including in therapy areas such as long-term weight management, while maintaining its emphasis on needle-free subcutaneous drug delivery.
• What new technologies is NuGen developing?
  NuGen reports that it is developing a new needle-free injection system featuring an internal sterile insulin cartridge, protected by international patent WO2021206553. The company describes this system as integrating a prefilled cartridge into its needle-free autoinjector, removing the need for external adaptors and manual filling, and incorporating a backflow control mechanism tailored to jet injection.
• How is NuGen funding its growth?
  NuGen has disclosed a non-brokered private placement of secured convertible debentures purchased by Sol‑Millennium Medical HK Limited and Nature Health Development (Hong Kong) Co. Limited. The company states that it intends to use the proceeds for working capital, expansion of production, and fulfillment of increasing global sales purchase orders.
• What corporate governance changes has NuGen reported?
  Following the strategic investment by Sol‑M and Nature Health, NuGen announced that shareholders approved these entities as Control Persons under TSX Venture Exchange policies. The company also reported appointments of new directors associated with these investors and later announced the appointment of a new Chief Executive Officer, along with acknowledgments of outgoing executives and directors.
• Is NuGen still an active company?
  The provided news releases describe ongoing product development, distribution expansion in Canada and France, a strategic partnership in the UK and other territories, financial reporting, and leadership changes. There is no mention in the supplied information of delisting, bankruptcy, or cessation of operations.